{
    "organizations": [],
    "uuid": "10e39b996dfb134422e4a3212f823b03d4853a2a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-ose-immunotherapeutics-receives-no/brief-ose-immunotherapeutics-receives-notice-of-allowance-for-new-patent-around-immuno-oncology-applications-idUSASM000IIG",
    "ord_in_thread": 0,
    "title": "BRIEF-Ose Immunotherapeutics Receives Notice Of Allowance For New Patent Around Immuno-Oncology Applications",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 25 (Reuters) - Ose Immunotherapeutics Sa:\n* OSE IMMUNOTHERAPEUTICS RECEIVES NOTICE OF ALLOWANCE FOR NEW PATENT BY U.S. PATENT AND TRADEMARK OFFICE THAT FURTHER STRENGTHENS INTELLECTUAL PROPERTY PORTFOLIO AROUND TEDOPIÂ® IN IMMUNO-ONCOLOGY APPLICATIONS Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-01-26T01:35:00.000+02:00",
    "crawled": "2018-01-26T21:29:15.009+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "ose",
        "immunotherapeutics",
        "sa",
        "ose",
        "immunotherapeutics",
        "receives",
        "notice",
        "allowance",
        "new",
        "patent",
        "patent",
        "trademark",
        "office",
        "strengthens",
        "intellectual",
        "property",
        "portfolio",
        "around",
        "application",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}